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Abstract
Cutaneous squamous cell carcinoma (cSCC) accounts for 25% of cutaneous 
malignancies diagnosed in the Caucasian population. Surgical removal in combina-
tion with radio- and chemotherapy is an effective treatment; however, prognosis 
for patients suffering from aggressive cSCC is still relatively poor. Increasing 
prevalence coupled with high mortality and morbidity in aggressive metastatic 
forms of cSCC highlights the need for development of novel targeted therapeutics. 
Metastasis is a complex process requiring dramatic reorganization of the cell cyto-
skeleton. Recent studies have highlighted the importance of mechanical forces and 
actin dynamics in cancer cells’ intrinsic ability to invade adjacent tissues, intravasate 
into vasculature, and ultimately metastasize. Tight regulation of the biochemi-
cal and mechanical properties of the actin cytoskeleton drives cellular processes 
involved in cSCC progression including polarity establishment, morphogenesis, and 
motility. Here we will provide a short introduction to disease pathogenesis, give an 
overview of the role of key regulatory proteins governing the mechanical forces and 
actin dynamics critical to cSCC progression, and describe the contribution of actin 
remodeling and actomyosin signaling to cSCC progression. We will also discuss how 
targeting protein regulating mechanical force and actin dynamics may have clinical 
utility in development of novel treatment modalities for patients suffering from 
aggressive cSCC.
Keywords: cutaneous squamous cell carcinoma, actin cytoskeleton remodeling, 
mechanical force, contraction, systemic therapy
1. Introduction
Cutaneous squamous cell carcinoma (cSCC) most commonly arises in actinically 
damaged skin and accounts for 25% of cutaneous malignancies diagnosed in the 
Caucasian population [1]. The incidence of cSCC continues to rise annually, with an 
estimated 50–200% increase in incidence in the last three decades in USA alone, and 
is predicted to increase in future years due to an aging global population [2]. Solar 
ultraviolet radiation is the primary environmental extrinsic cause of cSCC. Intrinsic 
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immunosuppression, the second most common cause, leads to the formation of 
aggressive cSCC in organ transplant patients, patients on immunomodulatory 
therapies, and those suffering from recessive dystrophic epidermolysis bullosa, a 
genetic skin blistering disease [3–5]. The incidence of cSCC is higher in individuals 
who are fair-skinned and have a sun-sensitive phenotype; however, the aggressive 
forms of cSCC are more common in men and the elderly [3]. Despite its prevalence, 
the relatively low fatality rate of cSCC means that its health and economic burden 
is often substantially underestimated [3], albeit latest data showing that in addition 
to significant morbidity cSCC accounts for up to 8000 deaths per year and costs 
approximately $4.8 billion annually in USA alone [6].
cSCC generally presents as a scaly, red or bleeding abnormal lesion on sun-
exposed areas, and is associated with relatively benign outcomes and a low 
risk of metastasis. However, cSCC can demonstrate dramatic histopathological 
heterogeneity, resulting in a wide range of clinical outcomes [7]. Histopathologic 
subtypes of cSCC are broadly divided into low-grade SCC (Figure 1A) that are 
well-differentiated but have low metastatic potential (keratoacanthomas, SCC 
in situ and verrucous carcinoma), or high-grade SCC (Figure 1B) that are poorly 
differentiated, have high potential of metastasis and recurrence, and are associated 
with a poor prognosis for patients (desmoplastic cSCC, adenosquamous cSCC and 
cSCC associated with non-healing ulcers or scarring processes arising from chronic 
wounds) [2, 7]. Once developed, the natural history of untreated SCC is one of 
local invasion followed by metastasis via the lymphatic system, blood or perineural 
invasion, which can lead to death [7]. In most cases, cSCCs are detected early and 
can be successfully eradicated by surgical excision. However, if not detected and/or 
left untreated, disease progression to high-grade cSCC will often lead to mortality. 
Clinically, the most powerful predictor of disease pathogenesis is nodal metastasis 
and size, followed by invasion beyond fat, location, and lastly perineural invasion. 
These parameters are used in clinical staging systems for cSCC [3]. Management 
of cSCC is primarily surgical, with adjuvant chemoradiation approaches based on 
risk factors, patient and tumor features, as well as care features including access to 
treatment and associated costs [2].
With increasingly longer life expectancy, the health and economic burden of 
cSCC is likely to continue to increase significantly. Hence, a better understanding of 
factors contributing to cSCC progression and metastasis is necessary to aid devel-
opment of novel therapies, aimed at combatting cSCC in the community. Despite 
Figure 1. 
Representative histopathological features of low-grade and high-grade cSCC. (A) Low-grade cSCC in situ 
with prominent dyskeratosis and aberrant mitosis at all levels of the epidermis, with marked parakeratosis 
and intact basement membrane. (B) High-grade poorly-differentiated cSCC lesions showing prominent 
keratinization and the formation of “pearl like” structures where dermal nests of keratinocytes attempt to 
mature. Adapted from Yanofsky et al. [7] and modified with approval.
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recent advances in gene expression screening technologies that have begun to 
identify candidate genes commonly mutated in patients with cSCC (including TP53, 
CDKN2A, Ras and NOTCH1), which may be responsible for regulating motility 
and invasion in cSCC, a comprehensive understanding of the factors contributing 
to cSCC invasion including mechanical tension and actin dynamics is still emerging 
[8]. One thing that is clear is that patient outcome directly correlates with the degree 
of local and regional invasion, and coordinated regulation of the actin cytoskeleton 
is critical to cell motility, invasion and metastasis [9]. Consequently, the signaling 
pathways involved in mediating chemotactic cues from the extracellular environ-
ment that regulate the actin cytoskeleton and mechanical forces, guiding cancer cell 
invasion and metastasis, have been and continue to be an area of intense study.
Recent studies have revealed a number of proteins and molecules that are 
aberrantly expressed in cSCC. These proteins link cell migratory signals to the actin 
cytoskeleton, thereby playing an instrumental role in the ability of cancer cells to 
resist chemotherapy and/or metastasize [10]. In this chapter we will describe the 
actin dynamics and mechanical force governing tumor cell migration, invasion and 
metastasis. We will outline the main signaling pathways governing the formation 
of invasive protrusions by cancer cells with regard to the function of key regulatory 
proteins involved in actin cytoskeleton remodeling in cSCC.
The metastatic spread of aggressive cancers, including cSCC, is a highly selective 
process involving a series of sequential and orchestrated steps in the so-called “meta-
static cascade”: detachment from the primary tumor site, cell migration and invasion 
of the surrounding extracellular matrix (ECM), intravasation into vasculature, 
extravasation at a secondary site, and interaction with the extracellular environment to 
form metastatic tumors [11]. Each of these steps offers the potential for design of dif-
ferent therapeutic approaches to combat aggressive cSCC. Indeed, a number of recent 
studies have identified novel therapeutic approaches including both adjuvant and 
neoadjuvant treatments, with clinical trials utilizing epidermal growth factor receptor 
inhibitors and immune checkpoint blockers (nivolumab, pembrolizumab, and ipilim-
umab) showing promising early results as potential treatments of cSCC [12]. Recent 
trials using cytotoxic chemotherapy have, however, shown limited advances for the 
treatment of cSCC, and trials investigating combined immune checkpoint inhibitor 
and radiation therapies, which may have synergistic effects in treatment of cSCC, are 
still pending [13]. This highlights the need for increased research to close the gaps in 
our knowledge of cSCC biology, including better understanding of the factors that lead 
to aggressive cSCC, the role of microbiomes and HPV infection, the role that mechani-
cal force and actin dynamics plays in this process, prediction of clinical response to 
therapies including immune checkpoint blockade, and how to tailor better prevention 
and treatment strategies to individual risk factors and needs [6]. Emerging evidence on 
the crosstalk between different components of the cytoskeleton in metastatic progres-
sion combined with clinical data illustrating strong relationships between cytoskeletal 
alterations and metastasis in various cancers pinpoints important opportunities 
for potential therapeutic targets [11]. Later in this chapter we will describe current 
research that has attempted to identify the steps of the metastatic cascade suitable and 
most amenable for therapeutic intervention, with a focus on harnessing our knowledge 
of actin cytoskeleton remodeling and mechanical forces to postulate therapeutic 
strategies targeting cytoskeletal and cytoskeletal-associated proteins critical in cSCC.
2. Cytoskeletal dynamics and regulation during cSCC progression
The skin is exposed to and responds to a wide range of mechanical signals 
throughout homeostasis and through to malignancy. Mechanical forces have been 
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shown to regulate these normal cellular processes including stem cell renewal, 
lineage differentiation and proliferation, wound healing, as well as transformation 
through changes in the actin cytoskeleton—the ability to protrude, adhere to the 
ECM, migrate through tissue and invade into the underlying basement membrane.
The types of mechanical forces exerted upon the skin can vary depending on 
the context. In homeostasis, tensile/stretch forces and compressive forces arise as a 
result of muscle and joint movements, and physical location—skin stretched over 
bone is under significantly more stress than when over fat or muscle [14]. Tensile 
forces cause cells to elongate and expand, and therefore are generated at sites of 
wounding as epithelial cells migrate in and contract to close the wound. This can 
generate scarring and fibrosis, which can lead to skin cancer including cSCC [15]. 
Compressive forces generate different biomechanics in skin cells compared to tensile 
force [16]. Compressive forces are able to activate Rho-ROCK signaling (described 
below) in the skin, which has been shown to play a role in tumor progression [17]. In 
melanoma, it was found that stress-bearing areas of the foot were more conducive to 
cancer development due to increased mechanical compressive stress [18]. Changes 
in substrate stiffness underlie these mechanical signals (Figure 2), and it has been 
shown that stiff stroma can lead to an activation of integrin signaling and subse-
quent cSCC development [19].
Cells have the ability to sense these changes in their environment (process 
referred to as “mechanosensing”). The mechanical signal is then converted to a 
biochemical signal in a process called mechanotransduction, and the biochemi-
cal signals initiate a cascade of changes within the cell at the transcriptional, 
translational and post-translational levels that result in a cell that can appropri-
ately and reciprocally respond to the extracellular signals (process referred to as 
“mechanoreciprocity”) [20]. In disease states including cSCC, the heightened and/
or constitutive extracellular signals generate a detrimental loop of ever-increasing 
mechanoreciprocal signaling, hence leading to enhanced tumor progression, inva-
sion and eventually metastasis [20].
Triggered by the changes in the cell microenvironment, the actin cytoskeleton 
undergoes a number of changes that allows a cell to become more motile and/or 
invasive. The ability of a cell to undergo directed migration is essential to its ability 
to metastasize, and is characterized by an ordered process (Figure 3) of membrane 
protrusion at the leading edge (filopodia and lamellipodia) and sides (invadopodia) 
Figure 2. 
Mechanical forces acting upon skin cells. The major types of mechanical forces experienced by skin cells are 
compressive (inward pushing) and tensile (stretching) forces, which in cSCC progression are generated by 
an increase in extracellular matrix stiffening. These are sensed by the cell, which then is able to respond 
accordingly.
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of the cell, contact and adhesion between the protrusion and the matrix, movement 
of the main cell body, and retraction of the trailing edge [21, 22]. Lamellipodia 
are flat membrane protrusions containing dendritic arrays of actin filaments that 
branch out like a sheet from the leading edge of a cell. This particular form of pro-
trusion is thought to have a major role in cell migration as their morphology allows 
the cell to make multiple contacts with the underlying substrate and pull the cell 
forward. Filopodia are narrow protrusions made up of bundled and cross-linked 
actin filaments that also stretch out from the leading edge. Invadopodia, unlike 
lamelli- and filopodia, are protrusions branching out from the sides of a cell, which 
have increased membrane remodeling and matrix degradation proteins [21]. These 
particular membrane protrusions are often seen in cancer cells including during 
cSCC progression [23].
Adhesions between the cancer cells and matrix are necessary for invasion and are 
largely mediated by integrins (discussed in detail below) [22]. During cSCC progres-
sion, there is an increase in cellular attachment to the ECM and, concurrently, a 
decrease in attachment to neighboring epithelial cells signified by a reduction in levels 
of E-cadherin expression. Following matrix adhesion, the trailing edge of the cell 
contracts, allowing the cell to move forward. Myosin II is required for this actin fila-
ment contraction, and is largely regulated by signaling through the small G-protein 
Rho. Once the cell contracts, its tail detaches as focal adhesion complex components 
are cleaved [22]. Actin remodeling proteins are essential in these processes, and often 
regulate cell-cell and cell-stroma attachment and turnover of focal adhesions, allow-
ing cell traction and movement to take place. The coordination of actin polymeriza-
tion and contraction allows the cSCC cell the ability to migrate through dense, stiff 
ECM and stroma to metastasize to lymph node or surrounding organs.
A number of different pathways are activated downstream of mechanical 
signals, causing changes in the actin cytoskeleton. Signaling pathways involved in 
cytoskeletal dynamics during cSCC progression are also activated as a result of con-
stitutive or heightened growth factor signaling [24]. Together, the combination of 
mechanical and biochemical signals can trigger a multitude of intracellular signal-
ing cascades that ultimately affect cell morphology. In this section, we will discuss 
the broad families of proteins regulating actin dynamics and mechanical forces in 
cSCC, an overview of which is illustrated in Figure 4. The overview provided in this 
chapter will not cover all the pathways or actin remodeling proteins involved but 
focus on those most relevant to cSCC progression, invasion and metastasis.
Figure 3. 
Cell motility as controlled by the actin cytoskeleton. Upon sensing of extracellular cues, intracellular signaling 
cascades generate cytoskeletal protrusions (lamellipodia and filopodia) at the leading edge containing actin 
filaments, as well as invasive protrusions (invadopodia) at the sides of the cell, necessary for cSCC invasion. 
The cell adheres to the matrix, forming integrin-mediated focal adhesions. The nucleus and cell body are then 
pushed forward as the trailing edge contracts, via stress fibers. The rear of the cell then detaches, allowing the 
cell to migrate forward.
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2.1 Mechanosensing: integrins
Integrins are well-characterized as the first point of contact for mechanical 
signal transduction. Inactive heterodimers on the cell surface, they are partially 
activated by intracellular proteins (“inside-out” signaling) before full activation 
upon binding to extracellular ligands (“outside-in” signaling) [25]. Binding to the 
extracellular ligand results in full activation of the integrin receptor and leads to 
the formation of either an intracellular focal adhesion complex to link the ECM 
to the actin cytoskeleton, or hemidesmosomes, linking the ECM to intermediate 
filaments. The integrin that is activated is context-dependent in regards to the 
particular focal adhesion complexes that are formed, broadly encompassing a range 
of adaptor proteins including: talin, vinculin, paxillin, Flightless I (Flii), focal 
Figure 4. 
Major pathways regulating cytoskeletal dynamics downstream of mechanical signals in cSCC. Graphical 
representation of signaling pathways which respond to mechanical force and govern downstream actin 
remodeling during cSCC progression.
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adhesion kinase (FAK) and integrin-linked kinase (ILK). FAK is rapidly recruited to 
focal adhesions upon integrin activation and is auto-phosphorylated, driving down-
stream signaling. FAK phosphorylation, stimulated by integrin activation, allows 
binding of Src-family kinases that are then able to trans-phosphorylate FAK. This 
leads to activation of ERK/MAPK signaling, and this complex is therefore able to 
control cell shape and regulate focal adhesions [26]. In cSCC, a step-wise increase in 
activation of FAK from unaffected margin skin to hyperproliferative skin and inva-
sive cSCC [27] results in elevated integrin-FAK-Src signaling that stimulates kera-
tinocyte migration [28] and drives progression of benign papillomas to aggressive 
cSCC [29, 30]. In cSCC, it has been demonstrated that FAK function is required for 
cancer stem cell maintenance, regulating cSCC initiation, growth, regression, and 
progression [31]. Actin remodeling protein Flii, which will be discussed in detail 
in Section 2.4, has been shown not to directly bind integrin receptors but form 
focal adhesion complexes with adaptor proteins and regulate integrin activation, 
downstream Src/paxillin signaling and focal adhesion turnover in a Rac1 dependent 
manner [25, 32]. Additionally, latest research has shown that actin remodeling 
proteins Flii and gelsolin, which have always been thought to be intracellular, have 
also both been shown to be secreted where they function to sequester extracellular 
actin post tissue injury, modulate inflammation and affect collagen VII anchor-
ing fibril formation. Flii is able to modulate inflammation via toll-like receptor 4 
(TLR-4) signaling, as Flii leucine-rich repeat (LRR) domains have 50% similarity to 
LRR domains of TLR-4, by which the immune system is able to detect infection or 
injury. The binding of LRRs to PAMP and DAMP molecules activates intracellular 
TLR signaling and ultimately results in the release of proinflammatory cytokine 
secretion [33]. The extracellular roles of Flii and gelsolin in respect to mechanosens-
ing and cSCC progression are still to be examined. Nevertheless, it is clear that the 
coordinated activation of integrin receptors, focal adhesion complex formation 
and downstream signaling stimulation is essential for cytoskeletal changes that are 
necessary for cell migratory and invasive capability during cSCC progression.
2.2 Mechanotransduction: Rho GTPases
Downstream of integrin activation are the Rho small GTPases, which are part of 
the Ras superfamily and key regulators of cell cytoskeletal dynamics through both 
actin polymerization and organization, hence driving cancer cell motility [34]. Of 
this subfamily, RhoA, Rac1 and Cdc42 are the best-characterized.
RhoA is involved in actomyosin contractility, formation of actin stress fibers and 
assembly of focal adhesion complexes. The main regulator of cytoskeletal dynamics 
leading to formation of stress fibers is myosin II, and its regulatory subunit myosin 
regulatory light chain-2 (MLC2) can be activated by RhoA signaling leading to 
contraction of actin fibers. Rho-associated kinases ROCK1 and ROCK2 are serine/
threonine kinases that contain a Rho-binding domain and are activated by RhoA in 
its active GTP-bound form, directly activate MLC2 via phosphorylation. Due to its 
roles in cell contractility and movement, Rho-ROCK signaling has been implicated 
as a driver for invasiveness during cSCC progression but also plays a positive role 
in physiological normal wound healing processes [35]. In human cSCCs, ROCK 
is not only highly expressed but also activated in the hyperproliferative skin and 
invasive regions of the tumor, as shown by phosphorylation of the ROCK substrate 
myosin phosphatase (MYPT1) [27]. In the skin, this ROCK-mediated actomyosin 
contractility is required for proliferation of the epidermis, as ROCK activation 
stabilizes β-catenin through phosphoinositide 3-kinase (PI3K), Akt, and inhibition 
of its phosphorylating kinase GSK3β [36]. During cancer progression from normal 
skin through to hyperproliferative and invasive cSCC, nuclear localization of active 
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β-catenin and inactivation of GSK3β is increased, accompanied also by a progressive 
increase in FAK activation [27, 36]. It has further been demonstrated that a negative 
regulator of ROCK signaling, 14-3-3ζ, is significantly down-regulated in human 
cSCCs. As genetic deletion of 14-3-3ζ results in significantly larger papillomas in the 
two-stage chemical carcinogenesis (DMBA-TPA) mouse model of SCC, this suggests 
that uncontrolled ROCK signaling can drive cSCC tumor growth [35].
Cdc42 is involved in formation of F-actin microspikes and filopodia in both 
normal and cSCC cells, by via actin polymerization at the leading edge and at the 
sides of the cells, contributing to cSCC invasion. Traf6 has been demonstrated to 
regulate Cdc42 to induce these F-actin microspikes in SCC cells [37]. When Cdc42 
is absent in keratinocytes, cells are no longer able to properly process and deposit 
ECM components or integrin receptors, hence halting cellular migration [38]. 
Taken together, these studies demonstrate roles for Cdc42 in both skin cell migra-
tion and invasion, necessary cellular processes for progression of cSCC. Cdc42 is 
necessary for proper cellular polarity in normal and migratory cells [34], and this in 
turn activates G-proteins of the Rac subfamily of Rho small GTPases [39].
Rac1 is hyperactivated in cSCC via integrins including α3β1, and is important 
for keratinocyte cell proliferation [40, 41]. Rac1 stimulates polymerization of actin 
via multiple kinase signaling cascades including that of MAP kinase (elevating the 
transcription factors AP-1, NFκB and CRE). This therefore allows the cell to form 
a branched actin network, necessary for leading-edge lamellipodia formation and 
membrane ruffling [42]. Indeed, actin remodeling protein, Flightless I (Flii), has been 
shown to regulate focal adhesion by inhibition of paxillin phosphorylation via a Rac1 
dependent pathway [32]. Rac1 can be activated by Tiam1, and it was shown in the two-
stage chemical carcinogenesis cSCC model that genetic deletion of Tiam1 significantly 
reduced tumor incidence, burden and growth. However, SCC tumors that did arise in 
Tiam-null mice were significantly more invasive and malignant, potentially due to a 
loss of cell-matrix adhesion [43]. This highlights the dual homeostatic and tumor- 
promoting roles that actomyosin regulatory pathways can play during cSCC progression.
Rho-associated kinase ROCK can also phosphorylate and activate LIM kinases 1 
and 2, which are then able to phosphorylate and inactivate cofilin, an F-actin sever-
ing protein, resulting in F-actin filament stabilization [44]. Accordingly, it has been 
shown that LIMK1 levels are increased in cSCC tumor tissue compared to normal 
skin, and that LIMK1 silencing can suppress cell growth and invasion in cSCC cell 
lines [45]. In addition, it has been suggested that LIMK is required in the microenvi-
ronment in leading fibroblasts, to allow for efficient remodeling of the ECM and sub-
sequent cSCC invasion [46]. It has been demonstrated that cofilin phosphorylation 
can be abolished by treating cSCC cells with LIMK inhibitors. This reduces β-catenin 
accumulation and epidermal proliferation via reversing actomyosin contractility [36], 
however clinical trials using these inhibitors are still pending. The involvement of Rho 
GTPases in cellular migration and invasion in cSCC due to cytoskeletal rearrange-
ment implicates this family of proteins as drivers of cancer initiation, progression and 
metastasis. Hence, targeting Rho pathway signaling, in particular that of RhoA-ROCK 
signaling, is an attractive therapeutic option that will be explored later in this chapter.
2.3 Actin polymerization: WASP, cortactin, and Arp 2/3
Actin nucleation promoting molecules are activated downstream of Rho 
GTPases and growth factor receptors. Wiskott-Aldrich syndrome protein (WASP) 
family members, via Erk, paxillin, and Src signaling together with cortactin, act to 
stimulate the actin-related protein (Arp) 2/3 complex which in turn mediates actin 
polymerization [47].
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The WASP family consists of WASP proteins and WASP-family verprolin-
homologous (WAVE) proteins. WASP proteins interact with Rho GTPases in order 
to form cellular protrusions and allow the cell to migrate, for example, N-WASP is 
involved in formation of filopodia and invadopodia upon its activation by Cdc42. 
WASP proteins bind to G-actin and Arp2/3 resulting in their activation and hence 
triggering actin filament production. WASP and WAVE proteins also bind profilin, 
which transports actin monomers onto the growing ends of actin filaments, and 
is therefore also an important factor in cell motility [47]. As a loss of N-WASP in 
keratinocytes causes epidermal hyperplasia and a reduction in epithelial cell tight 
junctions [48], this highlights the need for proper control of these processes. The 
formation of cellular protrusions also relies on the Src protein cortactin, which 
binds to and activates the Arp2/3 complex independently of WASP, thereby 
regulating actin filament nucleation. Cortactin binds to F-actin, stabilizing actin 
filaments and allowing it to properly activate Arp2/3 [49, 50]. In head and neck 
SCC, overexpression of cortactin increases cancer cell proliferation and increases 
cell survival in anchorage-independent conditions [51], while in oral SCC, silenc-
ing of cortactin was shown to significantly impair invasiveness and downregulate 
the levels of epithelial markers, indicating an epithelial to mesenchymal transition 
(EMT) [52], a process by which epithelial cells lose their adhesion to one another 
and acquire a migratory and invasive mesenchymal phenotype (discussed in further 
detail below). Indeed, Arp2/3 complex proteins are required for cell proliferation 
and migration in other forms of SCC [53, 54], and based on the Arp2/3 role in actin 
filament polymerization, it is clear that Arp2/3 is also critical for actin cytoskeletal 
remodeling leading to cancer cell motility and invasion.
2.4 Actin remodeling: tropomyosin, Flightless I, and podoplanin
The actin cytoskeleton is composed of three distinct elements including 
microfilaments, microtubules and intermediate filaments. Tight regulation of 
cytoskeletal elements must be coordinated, and latest research has shown that 
interplay between actin and microtubules is bidirectional [55]. Actin-based motility 
is also dependent on the balanced activity of number of specific actin remodeling 
proteins. In this section we will highlight main actin remodeling proteins that have 
been shown to have specific functions in cSCC progression, including members of 
the tropomyosin family of actin-associated proteins, the gelsolin family of actin 
remodeling proteins, and Podoplanin, a simple glycoprotein with important roles in 
cSCC progression.
Members of the tropomyosin family of actin remodeling proteins display a 
tissue- and time-specific expression, while their association with actin filaments 
impairs isoform-specific regulation of actin filament dynamics [56]. Tropomyosin 
proteins assemble as polymers in the major groove of the polymerized actin fila-
ment and their association drives actin filament turnover, hence playing an impor-
tant part in a number of cellular functions including motility and metastasis [57]. 
There are over 40 different isoforms of tropomyosin and few have been described 
as having an important role in cSCC progression. High expression of Tm5NM1, a 
specific cytoskeletal tropomyosin isoform, has been shown to inhibit cell migration 
and invasion as well as impair normal wound healing via its effects on Src activa-
tion, focal adhesion stabilization, increased actin filament tension, and paxillin 
phosphorylation [58]. Current research is examining the effect of Tm5NM1 inhibi-
tor TR100 on cSCC progression (see Section 3). On the other hand, downregula-
tion of tropomyosin-1 and complete loss of β-tropomyosin has been identified in 
human esophageal SCC, while α-tropomyosin has been shown to be preferentially 
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expressed in keratinocytes of the multistage model of murine cSCC, collectively 
suggesting isoform specific functions [59–61].
The dynamic remodeling of the actin cytoskeleton is also tightly regulated by 
the gelsolin family of actin remodeling proteins, which includes: gelsolin, villin, 
adseverin, capG, advillin, supervillin, and Flightless I (Flii) [62]. These actin 
binding proteins function in the cytoplasm of the cells where they control actin 
organization by severing pre-existing filaments, capping the fast growing filament 
ends and bundling filaments, enabling filament reassembly into new cytoskeletal 
structures that are required for cell motility, invasion and metastasis [63]. Studies 
have shown that downregulation of gelsolin proteins counteracts cancer cell inva-
sion in vitro [64], however in cSCC, gelsolin and Flii have been the most studied 
to-date. Gelsolin over-expression has been shown to promote cell growth and motil-
ity in oral SCC [64, 65], while Flii, through its effects on apoptosis, has been linked 
to promotion of breast cancer progression and invasion and progression of cSCC 
[23, 66]. Flii is an important regulator of cell adhesion, migration and proliferation 
and a number of previous studies have described the role of Flii protein in wound 
healing and demonstrated the therapeutic effect of Flii neutralizing antibodies 
(FnAb) in acute and chronic wounds, skin blistering diseases and inflammatory 
skin conditions [25, 32, 67–72]. Flii modulates cell adhesion and paxillin signaling, 
and regulates actin polymerization, tight junction formation and ECM produc-
tion during wound repair suggesting that similar roles may govern Flii activity in 
cSCC progression [23, 25, 32, 72]. Indeed, altering Flii levels both genetically and 
using Flii neutralizing antibodies significantly augments cSCC progression [23]. 
Therapeutic approaches targeting Flii in cSCC are described in Section 4.
The expression of Podoplanin, a small mucin-like protein, has also been linked 
to remodeling of the actin cytoskeleton in cSCC. Podoplanin is upregulated in the 
invasive front of a number of human carcinomas including cSCC and has been 
shown to induce collective cell migration by filopodia formation, via downregulat-
ing the function of Rho small GTPases [73, 74]. Podoplanin has also been linked to 
an increase in the migration of cancer-associated fibroblasts as well as endothelial 
network formation [75]. Collectively these findings suggest that Podoplanin is able 
to induce an alternative pathway of tumor cell invasion in the absence of traditional 
epithelial-mesenchymal transition.
Taken together, these studies highlight the important role of actin remodeling in 
cSCC progression and outline the importance of bidirectional stimulation of actin 
remodeling by both intrinsic factors and the microenvironment, critical to tumor 
invasion/metastasis. These findings provide a rationale for development of novel 
therapeutic strategies that target tumor invasion and metastasis.
3. Physiological effects of actin remodeling
Changes in the actin cytoskeletal structure result in changes to cell morphology, 
creating a cell more conducive to invasion. One of the commonly recognized require-
ments of metastasis is a cellular transition from epithelial to mesenchymal phenotype 
(EMT). This transition is characterized by upregulation of genes including vimentin, 
SNAI1 (snail), SNAI2 (slug) and Zeb1, and a downregulation of epithelial genes 
including cadherins, as well as concurrent loss of cell-cell junctions [76]. For example, 
in head and neck SCC an increase in matrix stiffness and hence increased mechani-
cal signaling caused an increase in EMT markers in tumor-initiating cells [71]. Cells 
undergoing EMT develop an elongated spindle-like morphology, due to the enhanced 
membrane protrusion formation [77]. It has been shown in A431 cells, a human epi-
dermal SCC cell line, that loss of T-cadherin induces elongation of cells and formation 
11
Mechanical Force and Actin Dynamics during Cutaneous Squamous Cell Carcinoma (cSCC)…
DOI: http://dx.doi.org/10.5772/intechopen.86041
of lamellipodia and multiple leading edges via changes in EGF-stimulated motility 
and invasion, as T-cadherin influences EGFR localization and responsiveness [78]. Of 
note, RhoA activation was also increased upon the loss of T-cadherin [79]. Likewise, 
Podoplanin is also capable of transforming cells to an invasive state without having to 
undergo EMT, due to rearrangements of the actin cytoskeleton [74].
The remodeling of the actin cytoskeleton also creates intracellular reciprocal 
forces that balance out the forces received by the cell from the extracellular micro-
environment. Actin polymerization extends the filament network, and as filaments 
in the leading edge are compressed between transient associations with the cell 
membrane and the bulk of the actin cytoskeletal network behind them, intracel-
lular force is generated. As protrusions are extended and retracted, actin filaments 
experience tension from transient bonds with the membrane, becoming bent or 
compressed [80]. Activation of the mechanotransduction pathways described 
above, downstream of ECM stiffness in cSCC, can also increase the propensity for 
augmented interactions with the stroma, and generate a tumor-promoting environ-
ment that enhances mechanoreciprocal signaling [20, 36].
4.  Therapeutic approaches targeting actin cytoskeletal regulatory 
pathways
Metastasis is a complex process requiring significant reorganization of the 
actin cytoskeleton and coordinated involvement of number of key proteins. These 
proteins interact directly and indirectly with both actin and microtubule networks, 
hence significantly influencing migratory and metastatic cell phenotypes. Strong 
clinical relationships between actin cytoskeletal alterations and cutaneous cancer 
metastasis have been previously described [11], offering potential opportunities for 
therapeutic intervention. For example, up-regulation of cortactin, an actin-binding 
adaptor protein in melanoma, has been directly linked to increased distal metastasis 
and reduced disease-free survival, while up-regulation of Ras mRNA has been 
directly linked to Stage III and Stage IV disease in head and neck SCC [81, 82]. The 
complex nature of cellular migration and invasion presents challenges in developing 
therapeutic approaches, as compensatory pathways may overcome the effects of 
specific inhibitors. This highlights the need for development of combinational and 
adjuvant therapies targeting multiple pathways that are involved in actin dynamics 
to treat aggressive cSCC. Pharmacological inhibitors of actin have failed clinical 
development due to non-specific effects on normal actin function in tissue, result-
ing in high levels of cardiotoxicity. Hence, research efforts have centered on thera-
peutic approaches that can modify signaling pathways regulating the actomyosin 
cytoskeleton and/or target cytoskeletal and cytoskeletal-associated proteins [11].
Increasingly it has been recognized that microRNAs (miRNAs) and long non-
coding RNAs (lncRNAs) are involved in regulating cytoskeletal dynamics through 
regulation of gene expression. lncRNAs have been shown to regulate lamellipodia 
formation by downregulating integrin expression in cSCC [83]. A number of miR-
NAs have also been shown to play a role in regulating cell cytoskeletal dynamics and 
interactions with stroma in cSCC, including: miR-340 [84], miR-20a [45], miR-31 
[85] and miR-125b [86]. These miRNAs act via inhibiting RhoA, LIMK1, WAVE3 
and matrix metalloproteinase (MMP)-13 respectively. The use of miRNAs in the 
clinic has clear potential, however clinical trials are yet to be undertaken.
One of the signaling pathways participating in regulation of cancer cell motility, 
invasion and metastasis is the ROCK signaling pathway, described in detail above. 
Hyperactivation of this pathway promotes cancer cell invasion in many solid tumors 
and studies have shown that Rho signaling through ROCK promotes the rounded 
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bleb-associated mode of amoeboid motility, thereby promoting tumor cell metasta-
sis [87]. Earlier reports have shown that treatment with the selective ROCK inhibi-
tor Y-27632 increases SCC cell adhesion, upregulates expression of E-cadherin, and 
decreases the phosphorylation of cofilin (thereby activating it), resulting in altered 
actin cytoskeleton rearrangement [88]. In the two-stage chemical carcinogenesis 
model, Y27632 treatment resulted in significantly smaller and fewer papillomas, 
with a reduced rate of cSCC conversion. This was associated with reduced collagen 
deposition in the ECM, which would indicate a decrease in mechanical signaling 
due to ECM stiffness [36]. This illustrates that inhibition of ROCK is a potential 
strategy for treatment of solid cancers including cSCC.
A potential upstream regulator of ROCK-mediated cell migration is gamma-
actin. Modulation of gamma-actin changes the directional cell migration via effects 
on microtubule dynamics and cell polarity, hence highlighting the crosstalk between 
actin cytoskeleton and microtubule signaling as a potential modality for targeting 
specific components of the network [89]. More recent studies, using newer genera-
tions of ROCK inhibitors and pharmacological small molecule inhibitors of the 
downstream effectors of ROCK that have micro-tubule stabilizing effects, are also 
showing some promise in regulating tumor metastasis, however no compounds are 
yet clinically approved [90]. Another potential therapeutic strategy is harnessing the 
ability of 14-3-3ζ, a negative regulator of ROCK signaling, to moderate mechanoreci-
procity in cSCC [35]. These approaches are particularly enticing due to the negative 
effects that clinical targeting of ROCK itself can potentially have [91].
Interestingly, studies investigating the interactions between SCC cells and 
cancer-associated fibroblasts have shown that ROCK activity is also an important 
requirement for adjacent stromal fibroblasts. ROCK activity positively influences 
the JAK1-STAT3 signaling pathway resulting in increased actomyosin contractility 
and proinflammatory cytokine secretion, favoring cSCC cancer cell invasion [92]. 
Consequently, these studies suggest that approaches aimed at inhibiting ROCK sig-
naling have the potential to interrupt both intrinsic and microenvironment-derived 
signals during cSCC progression.
Actin remodeling proteins have long been implicated in cSCC, as a dysregu-
lated actin cytoskeleton and an aberrant tumor microenvironment is a hallmark 
of aggressive cSCC [11, 93]. One particular actin remodeling protein, Flightless 
I (Flii), has been identified as a tumor promoter with transcriptional activity in 
colorectal, breast and hepatocellular carcinoma cell lines [66]. However, recent 
studies have also shown that Flii is significantly increased in human and mouse 
cSCC tissue samples, while secreted Flii is elevated in the sera of patients with 
cSCC and is increased in different cSCC cell lines established from human primary, 
recurring and metastatic cSCC as well as immortalized keratinocytes [23]. Human 
cSCC samples show positive staining for Flii in invading keratinocytes, surround-
ing tumor stroma and the outer hyperkeratotic layer of cSCC nodules present in 
the deep dermis [23]. Together, these data suggest that Flii is not only an important 
regulator of the actin cytoskeleton involved in cSCC progression but also a potential 
therapeutic target and diagnostic marker of cSCC severity. Indeed, overexpression 
of Flii resulted in severe cSCC development via evasion of apoptosis, while reducing 
Flii expression using intradermal injections of FnAb during cSCC initiation and 
progression significantly reduced Flii expression in both the tumor microenviron-
ment and in the serum, and led to significantly smaller tumor size (Figure 5) and 
decreased cellular sphere formation and invasion in vitro [23].
Remodeling and polymerization of actin filaments is critical during cSCC inva-
sion and formation of invadopodia. Increased Flii levels have shown to weaken cell-
stroma and cell-cell adhesions via alteration of GTPase and Src/paxillin signaling 
pathway activity [32] and augmented integrin-facilitated cell migration [25]. This 
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promotes tumor progression and facilitates invadopodia formation and subsequent 
tumor invasion into surrounding tissue [23]. Indeed, Flii is significantly increased 
in invading cSCC and has been demonstrated to associate with cortactin at leading 
edges of invadopodia and to regulate the invasive properties of cSCC keratinocytes 
[23]. Systemic and topical therapeutic approaches using FnAb are currently in 
development with FnAb as a therapy for wound healing now entering the final pre-
clinical validation stage [68, 94]. Flii has been shown to colocalize with structural 
(Claudin-1, -4 and -6) and adaptor (ZO-1 and -2) tight junction proteins and its 
overexpression in keratinocytes results in an altered F-actin/G-actin ratio, which can 
be restored using FnAb [72]. Therefore, taken together, these studies suggest that 
therapies targeting Flii may be a potential strategy for reducing the severity of cSCC 
in the community, however clinical trials using FnAb are still pending.
Pharmacological inhibition of actin-associated proteins aimed at compromising the 
survival and invasion of tumor cells may also have clinical benefit. One example of this 
strategy is harnessing TR100 inhibition of the tropomyosin isoform Tm5NM1. Tm5NM1 
belongs to a family of actin-associated proteins that regulate the activity of several 
effectors of actin filament dynamics [95], as described above. The TR100 inhibitor has 
been shown to preferentially disrupt the actin cytoskeleton of tumor cells, impairing 
tumor cell motility and viability, and reducing melanoma growth both in vitro and  
in vivo. This therefore provides a pathway for development of a novel class of anti-actin 
compounds for the potential treatment of wide variety of cancers including cSCC [96].
Figure 5. 
Reducing Flii expression prior to initiation and development of cSCC using FnAb results in decreased cSCC 
progression. As Flii is increased in human SCC samples, the effect of preventative FnAb treatment prior to SCC 
induction was investigated in FliiTg/Tg mice. Mice were treated with FnAb 2 weeks prior to cSCC induction and 
every second week throughout the trial and SCC development. (A and B) Reducing Flii levels in mice skin using 
preventative FnAb treatment prior to cSCC induction and during development resulted in decreased tumor 
progression and size relative to IgG control mice that have significantly larger and more developed necrotic and 
ulcerated tumors. (n = 12/treatment) Mean ± SD *p < 0.05. (C) Representative images of H&E stained tumors 
treated with FnAb or IgG control show more severe ulcerated tumor pathology in the IgG control group (black 
arrows). Scale Bars = 500 μm and 100 μm.
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Microtubule targeting agents of both synthetic and natural design, and microtu-
bule stabilizing and destabilizing agents, have been the focus of anti-cancer therapy 
in the last decade and remain one of the most successful group of agents in the clinic 
[97, 98]. Their ability to regulate the tubulin-microtubule equilibrium disrupts 
the mitotic spindle, halting the cell cycle and resulting in cell death. They have 
been shown to be effective in combination with anti-angiogenic and anti-vascular 
properties and in some cases have demonstrated the ability to overcome multi-drug 
resistance, supporting their utilization as a chemotherapy [99]. Epothilones are a new 
class of anti-microtubule agents currently in clinical trials. Epothilones have shown 
activity in cSCC cell lines and in melanoma clinically, however clinical trials on cSCC 
patients are still pending [100, 101]. Other examples of microtubule-targeting agents, 
which have shown clinical promise in different subtypes of SCC including metastatic 
and recurrent disease, include semisynthetic compounds docetaxel and eribulin 
and a natural compound called rhizoxin [102–104]. While microtubule-targeting 
compounds are widely used as chemotherapeutic agents, they do have variability in 
different cancers, cancer cells frequently develop resistance to them, and they can 
be toxic to normal tissue, highlighting the need for better research and refinement 
of these compounds as well as a need to further understand their interactions with 
microtubule-associated proteins [105]. It is possible that microtubule-targeting agents 
also exert broader effects on tumor cell migration, invasion and metastasis and future 
studies should explore their effects on cSCC in combination with actin pathway 
inhibitors. Gaining a better understanding on the interplay of regulatory proteins 
governing the mechanotransduction and actin cytoskeletal remodeling involved in 
tumor cell migration, invasion and metastasis will lead to increased efforts to exploit 
therapeutic avenues targeting the actin cytoskeleton to treat aggressive cSCC.
5. Conclusions
The contribution of actin cytoskeletal remodeling and actomyosin signaling 
during SCC progression is significant and cannot be undervalued in the search for 
new treatment modalities. Recent research has identified a number of potential 
novel therapeutic targets within regulatory actin and microtubule signaling path-
ways that should be explored as potential therapeutic adjuvants to immunomodula-
tory therapies currently in clinical trials. A comprehensive understanding of the 
regulatory network of cutaneous mechanotransduction, mechanical forces and 
actin dynamics in cSCC, as discussed in this chapter, will facilitate the development 
of novel approaches to curb the incidence and progression of aggressive cSCC in 
the community, generating new inroads toward development of novel, individually 
personalized and efficient therapeutic approaches.
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Nomenclature
Akt protein kinase B—serine/threonine-specific protein kinase
AP-1 activator protein 1—transcription factor that regulates various 
cellular processes downstream of stimuli
Arp2/3 actin-related proteins 2/3 complex—protein complex regulating 
the actin cytoskeleton
Cdc42 cell division control protein 42—protein involved in regulation of 
cell cycle
CDKN2A cyclin-dependent kinase inhibitor 2A
CRE cAMP-response element
cSCC cutaneous squamous cell carcinoma
DAMPs damage-associated molecular pattern molecules
DMBA 7,12-dimethylbenz[a]-anthracene—polycyclic aromatic hydrocar-
bon that acts as a carcinogen
ECM extracellular matrix
EGF epidermal growth factor
EGFR epidermal growth factor receptor
EMT epithelial to mesenchymal transition
Erk extracellular signal-regulated kinase—kinase involved in regula-
tion of cellular processes such as meiosis and mitosis
FAK focal adhesion kinase—a focal adhesion-associated protein kinase 
involved in cellular adhesion
Flii Flightless I
FnAb Flii neutralizing antibody
GSK3β glycogen synthase kinase 3-beta—serine/threonine protein kinase
GTPase enzyme that binds and hydrolyzes guanosine-5′-triphosphate
H&E hematoxylin and eosin
HPV human papillomavirus
ILK integrin-linked kinase
JAK janus kinase
LIMK LIM-domain kinase
lncRNA long non-coding RNA
MAPK mitogen-activated protein kinase
miRNA microRNA
MLC2 myosin regulatory light chain-2—subunit of myosin, which 
regulates cell contractility
MMP matrix metalloproteinase—endopeptidases that degrade various 
ECM proteins
MYPT1 myosin phosphatase target subunit 1—subunit of myosin phos-
phatase, which dephosphorylates MLC and thereby opposes 
contractility
NFκB nuclear factor kappa-light-chain enhancer of activated B cells—
protein complex that regulates transcription and other cellular 
processes
PAMPs pathogen-associated molecular pattern molecules
PI3K phosphoinositide 3-kinase—intracellular signal transducer 
enzymes ROCK: Rho-associated coiled-coil containing kinases
SNAI1 snail—transcription factor promoting repression of E-cadherin
SNAI2 slug—transcription factor promoting repression of E-cadherin
STAT signal transducer and activator of transcription proteins—intracel-
lular transcription factor
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Tiam1 T-lymphoma invasion and metastasis-inducing protein 1—regu-
lates Rho-like proteins and transduces extracellular signals
TP53 tumor protein p53
TPA 12-o-tetradecanoylphorbol-13-acetate—tumor promoting phorbol 
ester
TLR-4 toll-like receptor 4—transmembrane receptor that activates NFκB 
signaling
Tm5NM1 tropomyosin isoform 5NM1
Traf6 tumor necrosis factor (TNF) receptor associated factor 6
WASP Wiskott-Aldrich syndrome protein
WAVE WASP-family verprolin-homologous
Zeb1 zinc-finger E-box-binding homeobox 1—transcription factor that 
induces EMT by repression of E-cadherin and other genes
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